FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer.
FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer.
复制标题
FAT10与非小细胞肺癌的恶性程度和耐药性相关。
DOI：
10.2147/ott.s98410
复制
发表时间：
2016
影响因子：
4
通讯作者：
Cai L
中科院分区：
文献类型：
--
作者：
Xue F;Zhu L;Meng QW;Wang L;Chen XS;Zhao YB;Xing Y;Wang XY;Cai L
Lung cancer has become one of the leading causes of cancer mortality worldwide, and non-small-cell lung cancer (NSCLC) accounts for ~85% of all lung cancer cases. Currently, platinum-based chemotherapy drugs, including cisplatin and carboplatin, are the most effective treatment for NSCLC. However, the clinical efficacy of chemotherapy is markedly reduced later in the treatment because drug resistance develops during the treatment. Recently, a series of studies has suggested the involvement of FAT10 in the development and malignancy of multiple cancer types. In this study, we focused our research on the function of FAT10 in NSCLC, which has not been previously reported in the literature. We found that the expression levels of FAT10 were elevated in quick chemoresistance NSCLC tissues, and we demonstrated that FAT10 promotes NSCLC cell proliferation, migration, and invasion. Furthermore, the protein levels of FAT10 were elevated in cisplatin- and carboplatin-resistant NSCLC cells, and knockdown of FAT10 reduced the drug resistance of NSCLC cells. In addition, we gained evidence that FAT10 regulates NSCLC malignancy and drug resistance by modulating the activity of the nuclear factor kappa B signaling pathway.
